91高清自产国产拍,无码免费A级毛片大全,日本 欧美 国产中文字幕,99re热视频这里只有精品视频首页

complement C5

有货

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
rp173718-500μg 500μg 期货 Stock Image
rp173718-1mg 1mg 期货 Stock Image

基本描述

产品名称 complement C5

产品规格参数

CAS编号和信息 rp173718

关联配体

Ligand ID 8712
名称 complement C5
类别 Peptide
学名 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价 The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价 This is the full length, pre-pro-protein structure as represented in NCBI Reference Sequence: NP_001726. This peptide is cleaved into the complement C5 beta chain, complement C5 alpha chain and C5a anaphylatoxin (see the UniProt entry for the human protein P01031).

C5 inhibition is a clinically validated mechanism that is utilised for the control and suppression of complement-induced hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). is a clinically approved anti-C5 monoclonal antibody for PNH. Investigational Phase 1/2 anti-C5 monoclonal RG6101 (SKY59 ; IMGT 783) was granted FDA orphan drug designation in September 2017 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharmaceuticals is developing a C5 binding synthetic 15-amino-acid macrocyclic peptide (designated research code RA101495; Phase 2) for PNH and other complement-mediated illnesses. RA101495 was granted FDA orphan drug designation for PNH in July 2017. RA101495 binds to a site on C5 distinct from the binding site, with the aim of overcoming eculizumab resistance, such as that observed in patients with the Arg885His C5 variant (note that RA101495 is also effective against this variant ). It is also designed for subcutaneous self-administration, which would be more convenient for patients, who must be given eculizumab by i.v. infusion by a healthcare professional.

SARS-CoV-2 and COVID-19: Clinically approved and investigation candidates that target C5 are being evaluated in a number of clinical trials to determine their potential to combat complement-mediated inflammatory tissue damage in the organs of pateints with severe COVID-19.
配体家族 Complement components and ligands
基因/前体
Gene symbol Gene name Precursor protein name Species 别名
C5 complement C5 prepro-C5 Human CPAMD4, complement component 5
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰

参考文献

1. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T et al..  (2014)  Genetic variants in C5 and poor response to eculizumab..  N Engl J Med,  370  (7):  (632-9).  [PMID:24521109]
2. Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H et al..  (2017)  Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases..  Sci Rep,  (1):  (1080).  [PMID:28439081]

相关文档

质检报告COA

请输入批号:


产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

91高清自产国产拍,无码免费A级毛片大全,日本 欧美 国产中文字幕,99re热视频这里只有精品视频首页

品牌简介

{转码主词}